Fate Therapeutics (FATE) SEC Filings: History & Chart

Fate Therapeutics, Inc.(FATE)

Biotechnology · San Diego, CA

$2.29-0.14 (-5.76%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.

San Diego, CA

161 employees

www.fatetherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Bahram Valamehr

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 28, 2026	Sep 28, 2026	View filing
S-8	Aug 13, 2026	Aug 13, 2026	View filing
10-Q	Aug 13, 2026	Aug 13, 2026	View filing
8-K	Aug 13, 2026	Aug 13, 2026	View filing
4	Aug 5, 2026	Aug 5, 2026	View filing
4	Aug 5, 2026	Aug 5, 2026	View filing
SC 13G/A	Jul 8, 2026	Jul 8, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
3	Jun 15, 2026	Jun 15, 2026	View filing
8-K	Jun 15, 2026	Jun 15, 2026	View filing
8-K	Jun 4, 2026	Jun 4, 2026	View filing
4	May 21, 2026	May 21, 2026	View filing
4	May 21, 2026	May 21, 2026	View filing
10-Q	May 13, 2026	May 13, 2026	View filing
8-K	May 13, 2026	May 13, 2026	View filing
4	May 7, 2026	May 7, 2026	View filing
4	May 6, 2026	May 6, 2026	View filing
4	May 6, 2026	May 6, 2026	View filing
ARS	Apr 24, 2026	Apr 24, 2026	View filing
DEFA14A	Apr 24, 2026	Apr 24, 2026	View filing
DEF 14A	Apr 24, 2026	Apr 24, 2026	View filing
4/A	Apr 23, 2026	Apr 23, 2026	View filing

SEC Filings

Recent Filings